Becton Dickinson and Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

$BDX
Medical/Dental Instruments
Health Care
Get the next $BDX alert in real time by email
bdx-20250128
0000010795false00000107952025-01-282025-01-280000010795exch:XNYSus-gaap:CommonStockMember2025-01-282025-01-280000010795exch:XNYSbdx:Notes1.900dueDecember152026Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes3.020dueMay242025Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes1.208dueJune42026Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes1213DueFebruary122036Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes0034DueAugust132025Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes3.519DueFebruary82031Member2025-01-282025-01-280000010795exch:XNYSbdx:Notes3.828DueJune72032Member2025-01-282025-01-28

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) January 28, 2025
BECTON, DICKINSON AND COMPANY
(Exact Name of Registrant as Specified in Its Charter)
New Jersey
(State or Other Jurisdiction of Incorporation)
001-4802 22-0760120
(Commission File Number) (IRS Employer Identification No.)
  
1 Becton Drive, Franklin Lakes,
New Jersey
 07417-1880
(Address of Principal Executive Offices) (Zip Code)
(201) 
847-6800
 (Registrant’s Telephone Number, Including Area Code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
 
Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:



Title of Each ClassTrading Symbol
Name of each exchange on
which registered
Common stock, par value $1.00BDXNew York Stock Exchange
1.900% Notes due December 15, 2026BDX26New York Stock Exchange
3.020% Notes due May 24, 2025BDX25New York Stock Exchange
1.208% Notes due June 4, 2026BDX/26ANew York Stock Exchange
1.213% Notes due February 12, 2036BDX/36New York Stock Exchange
0.034% Notes due August 13, 2025BDX25ANew York Stock Exchange
3.519% Notes due February 8, 2031BDX31New York Stock Exchange
3.828% Notes due June 7, 2032BDX32ANew York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐




Item 5.07.    Submission of Matters to a Vote of Security Holders.

BD held its 2025 Annual Meeting on January 28, 2025. The final voting results for each of the matters submitted to a vote of shareholders at the 2025 Annual Meeting are as follows:

Proposal No. 1: All of the Board of Directors’ nominees for director were elected to serve for a term of one year and until their respective successors are elected and qualified, by the votes set forth in the table below.

Nominee
  For
     Against
    Abstain
Broker Non-Votes
William M. Brown229,666,7464,701,855364,72121,170,297
Catherine M. Burzik222,460,1217,797,9054,475,29621,170,297
Carrie L. Byington233,523,789852,341357,19321,170,297
R. Andrew Eckert212,988,07821,443,621301,62321,170,297
Claire M. Fraser223,419,29111,060,117253,91421,170,297
Jeffrey W. Henderson213,692,26820,691,456349,59821,170,297
Christopher Jones219,391,80115,072,728268,79221,170,297
Thomas E. Polen214,682,47818,775,4931,275,35221,170,297
Timothy M. Ring233,071,1381,320,264341,91921,170,297
Bertram L. Scott222,906,99211,548,073278,25721,170,297
Joanne Waldstreicher231,633,8562,805,606293,86021,170,297



Proposal No. 2: The appointment of Ernst & Young as BD’s independent registered public accounting firm for fiscal year 2025 was ratified by the shareholders by the votes set forth in the table below.
For AgainstAbstainBroker Non-Votes
235,180,130 20,249,859 473,629N/A

Proposal No. 3The shareholders approved, on an advisory, non-binding basis, the compensation of BD’s named executive officers by the votes set forth in the table below.
For AgainstAbstain Broker Non-Votes
208,413,830 25,696,707 622,784 21,170,297







ITEM 9.01.    FINANCIAL STATEMENTS AND EXHIBITS.
Exhibit 104    Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)
By:/s/ Stephanie M. Kelly
 Stephanie M. Kelly
 Associate General Counsel, Securities and Governance and Assistant Secretary
Date: January 31, 2025

Get the next $BDX alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BDX

DatePrice TargetRatingAnalyst
10/1/2024$255.00 → $275.00Neutral → Buy
Citigroup
5/30/2024$274.00Buy
Goldman
7/24/2023$305.00Mkt Perform → Outperform
Raymond James
5/30/2023$295.00Overweight
Morgan Stanley
5/5/2023$260.00 → $290.00Neutral → Overweight
Piper Sandler
4/12/2023$304.00Sector Weight → Overweight
KeyBanc Capital Markets
1/3/2023$250.00 → $290.00Neutral → Buy
BofA Securities
12/12/2022$221.00 → $250.00Sell → Neutral
Citigroup
More analyst ratings

$BDX
Press Releases

Fastest customizable press release news feed in the world

See more
  • BD Launches Next Generation Hemodynamic Monitoring Solution Providing Clinicians with AI-Driven Clinical Decision Support

    HemoSphere Alta™ Advanced Monitoring Platform with Predictive, Smart Algorithms Helps Clinicians Proactively Address Instability in Blood Flow and Pressure in Critical Situations FRANKLIN LAKES, N.J., April 21, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, has launched a new advanced hemodynamic monitoring platform with predictive, artificial intelligence (AI) based algorithms that can help clinicians proactively address blood pressure instability and optimize blood flow to help avoid potential life-threatening situations during procedures.     

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD to Announce Financial Results for its Second Quarter of Fiscal 2025

    FRANKLIN LAKES, N.J., April 3, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced that BD management will host an audio webcast at 8 a.m. ET on Thursday, May 1, 2025 to discuss the Company's financial results for its second quarter of fiscal year 2025, which ended on March 31, 2025, and to provide an update on its operations and strategy. The audio webcast can be accessed at BD's investor relations website at www.bd.com/investors, and a replay will be made available shortly after the call at the same website. Prior to the call, the Company will issue a news release and related presentation materials that will inclu

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Named One of America's Most Innovative Companies by Fortune

    FRANKLIN LAKES, N.J., March 31, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today was named to Fortune's 2025 list of America's Most Innovative Companies, ranking in the top 25% of companies overall. The list recognizes organizations that excel in developing innovative products, streamlining processes, and cultivating a forward-thinking corporate culture. "As one of the largest manufacturers of medical devices in the world whose products touch billions of patients around the globe, building on our long histor

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BDX
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$BDX
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BDX
SEC Filings

See more

$BDX
FDA approvals

Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

See more
  • November 23, 2021 - Coronavirus (COVID-19) Update: November 23, 2021

    For Immediate Release: November 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: On Nov. 22, the FDA authorized three over-the-counter (OTC) COVID-19 antigen diagnostic tests for people age 14 years or older with a self-collected nasal swab sample or people age 2 years or older when an adult collects the nasal swa

    $BDX
    Medical/Dental Instruments
    Health Care
  • July 23, 2021 - Coronavirus (COVID-19) Update: July 23, 2021

    For Immediate Release: July 23, 2021 The U.S. Food and Drug Administration today announced the following actions taken in its ongoing response effort to the COVID-19 pandemic: The agency updated its FDA COVID-19 Response At-A-Glance Summary, which provides a quick look at facts, figures and highlights on the FDA's response efforts. On Thursday, July 22 the FDA issued an Emergency Use Authorization (EUA) to Bec

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Leadership Updates

Live Leadership Updates

See more
  • BD Names Gregory J. Hayes to Board of Directors

    FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of extensive executive experience, having held chief executive officer and senior leadership roles across finance, corporate strategy and business development f

    $BDX
    Medical/Dental Instruments
    Health Care
  • Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors

    SAN DIEGO, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. ("Maravai" or the "Company") (NASDAQ:MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that Carl Hull will retire from his position as Executive Chairman of the Board and that the Board of Directors has unanimously elected R. Andrew Eckert to succeed him as Chairman of the Board, effective December 5, 2024. Carl Hull founded Maravai in 2014 and served as Chief Executive Officer, assuming the role of Executive Chairman in October 2022. "Leading Maravai has been the single most rewarding experience in my career. I am extremely proud of what we have

    $BDX
    $FTRE
    $MRVI
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Biotechnology: Pharmaceutical Preparations
  • Revelyst Announces Chief Supply Chain Officer

    Revelyst is thrilled to appoint longtime supply chain and business operations leader Joe Beck to the position of Chief Supply Chain Officer. Revelyst, a collective of world-class maker brands that design and manufacture performance gear and precision technologies and a segment of Vista Outdoor Inc. (NYSE:VSTO), today announced the appointment of Joe Beck as Chief Supply Chain Officer, effective April 22. In the third quarter, Revelyst launched GEAR Up, the company's plan to simplify its business model, deliver increased efficiency and profitability, and reinvest in its highest potential brands to accelerate growth and transformation. The appointment of a seasoned, transformational supply

    $BDX
    $EMBC
    $VSTO
    Medical/Dental Instruments
    Health Care
    Ordnance And Accessories
    Industrials

$BDX
Financials

Live finance-specific insights

See more
  • BD Reports First Quarter Fiscal 2025 Financial Results

    Company Delivers Revenue, Margin and Earnings Ahead of its Expectations Revenue of $5.2 billion increased 9.8% as reported, 9.6% currency-neutral and 3.9% organicGAAP and adjusted diluted EPS of $1.04 and $3.43 grew 8.3% and 28.0%, respectivelyBD completes $750 million share repurchase to date in FY25Company increases FY25 adjusted diluted EPS guidance at the midpoint while absorbing translational currency1FRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced results for its fiscal 2025 first quarter which ended December 31, 2024. "We delivered strong operational performance in Q1, with

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Announces Intent to Separate Biosciences and Diagnostic Solutions Business to Enhance Focus, Drive Growth and Unlock Value

    Compelling opportunity expected to unlock substantial value through enhanced focus, tailored investment and capital allocation, and optimized market valuation "New BD," built on momentum of BD 2025 strategy, will be well-positioned as a scaled, pure-play MedTech leader focused on attractive categories shaping the future of health careBiosciences and Diagnostic Solutions to realize its full market potential as differentiated leader in Life Sciences Tools and Diagnostics, with robust innovation pipeline and headroom for growth in key sectorsFRANKLIN LAKES, N.J., Feb. 5, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announ

    $BDX
    Medical/Dental Instruments
    Health Care
  • BD Board Declares Dividend, Authorizes 10 Million Additional Share Repurchases; BD Completed $750 Million Repurchase to Date in FY25

    FRANKLIN LAKES, N.J., Jan. 28, 2025 /PRNewswire/ -- The Board of Directors of BD (Becton, Dickinson and Company) (NYSE:BDX), a leading global medical technology company, today announced it has declared a quarterly dividend of $1.04 per common share, payable on March 31, 2025 to holders of record on March 10, 2025. The indicated annual dividend rate is $4.16 per share. The company also announced it repurchased $750 million in BD stock to date in fiscal 2025. In addition, the board has authorized the company to repurchase up to 10 million shares of BD common stock in addition to the shares that remain available under the board's previous authorization in 2021. The authorizations provide the c

    $BDX
    Medical/Dental Instruments
    Health Care

$BDX
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more